2022 ASCO Genitourinary Cancers Symposium - Episode 3

Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

Results from the phase 1 CHRYSALIS-2 trial (NCT04077463) were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Catherine A. Shu, MD, clinical director of the Thoracic Medical Oncology Service at Columbia University Herbert Irving Comprehensive Cancer Center, spoke to CancerNetwork® regarding the results. The findings presented included those from cohort A of patients non–small cell lung cancer harboring EGFR exon 19 deletions or L858R mutations who have previously been treated with osimertinib (Tagrisso) and platinum-based chemotherapy and are now being given amivantamab (Rybrevant) plus lazertinib (Laclaza).

In 162 patients treated in the cohort, the overall response rate observed was 33% (95% CI, 26%-41%), with a median duration of response of 9.6 months (95% CI, 7.0-not evaluable). Two patients (1%) had a complete response and 52 (32%) had a partial response.


This was in a heavily pretreated patient population. We had 2 sets of patients. One was just pretreated with osimertinib and chemotherapy only and then the other was a more heavily pretreated patient population. Some of those patients had up to 14 lines of prior therapy, showing that we can still get a good response rate in patients who have been heavily pretreated. This is a chemotherapy-free regimen which a lot of our patients are looking for. The last thing is that we did all this without biomarker selection. We didn’t need a particular biomarker to see a response. For future studies, we’re still examining what biomarkers may be the best but for now, we’re seeing responses in patients with EGFR- and MET-based mechanisms of resistance and other unknown mechanisms of resistance, but there’s no clear biomarker yet.


Shu CA, Goto K, Ohe Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. J Clin Oncol. 2022;40(suppl 16):9006. doi:10.1200/JCO.2022.40.16_suppl.9006